Does overt hepatic encephalopathy cause persistent cognitive defects even after successful liver transplantation?
Sanath Allampati, Kevin D. Mullen – 25 June 2014
Portal vein thrombosis in patients with cirrhosis
Thomas D. Boyer, Shahid Habib – 25 June 2014 – Watch a video presentation of this article
Benign and malignant hepatocellular lesions in patients with vascular liver disease
Valérie Vilgrain, Pierre‐Emmanuel Rautou, Valérie Paradis, Maxime Ronot – 25 June 2014 – Watch a video presentation of this article
Direct intranodal lymphangiography for recurrent chylous ascites following liver‐kidney transplantation
Aaron M. Williams, Thomas M. Seay, Jonathan C. Hundley, Roberto Gedaly – 25 June 2014
Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis
Mélanie Vallin, Olivier Guillaud, Olivier Boillot, Valérie Hervieu, Jean‐Yves Scoazec, Jérôme Dumortier – 25 June 2014 – Nonalcoholic fatty liver disease (NAFLD) is a potential long‐term complication after liver transplantation (LT) and can occur as recurrent disease in patients undergoing transplantation for NAFLD or as de novo NAFLD in others. The aim of this study was to compare these 2 different entities.
Management of disordered hemostasis and coagulation in patients with cirrhosis
Nicolas M. Intagliata, Stephen H. Caldwell – 25 June 2014 – Watch a video presentation of this article
New all‐oral HCV therapies for genotype 1: A final good‐bye to interferon
Anna S.F. Lok – 25 June 2014 – Watch a video presentation of this article
Management of disordered hemostasis and coagulation in patients with cirrhosis
Nicolas M. Intagliata, Stephen H. Caldwell – 25 June 2014 – Watch a video presentation of this article
Benign and malignant hepatocellular lesions in patients with vascular liver disease
Valérie Vilgrain, Pierre‐Emmanuel Rautou, Valérie Paradis, Maxime Ronot – 25 June 2014 – Watch a video presentation of this article
Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients
Masatoshi Ishigami, Takashi Honda, Yoji Ishizu, Yasuharu Onishi, Hideya Kamei, Kazuhiko Hayashi, Yasuhiro Ogura, Yoshiki Hirooka, Hidemi Goto – 25 June 2014 – The combination of nucleos(t)ide analogues (NAs) and hepatitis B immune globulin has been established as safe and effective prophylaxis against hepatitis B virus (HBV) reactivation after liver transplantation (LT). However, the essential weak point of this regimen is its high cost.